Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00803894 | A Clinical Study to Determine Biomarkers of Response to a Gamma Secretase Inhibitor | PHASE1 | COMPLETED | 30 | — | — | Dec 1, 2008 | Jan 1, 2009 | Jun 17, 2016 | - | — |
| Arm | Type | Description |
|---|---|---|
| A | ACTIVE_COMPARATOR | MK0752 1000 mg |
| B | ACTIVE_COMPARATOR | MK0752 350 mg |
| C | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| MK0752 | DRUG | Single dose MK0752 capsules, 1000 mg: there will be a 7-day washout period between treatments. |
| Comparator: MK0752. | DRUG | Single dose MK0752 capsules, 350 mg: there will be a 7-day washout period between treatments. |
| Comparator: Placebo | DRUG | Single dose placebo capsules: there will be a 7-day washout period between treatments. |
Inclusion Criteria: * Patient is a male * Patient has no clinically significant abnormality on electrocardiogram performed * Patient agrees to not to consume apple juice, grapefruit or grapefruit products beginning 2 weeks prior to first dose of study drug and for the duration of the study * Patien...